Survival after long-term ART exposure: findings from an Asian patient population retained in care beyond 5 years on ART [0.03%]
长期抗逆转录病毒治疗后的生存率：亚洲患者人群在接受超过5年的治疗后仍持续护理的发现
Rimke Bijker,Sasisopin Kiertiburanakul,Nagalingeswaran Kumarasamy et al.
Rimke Bijker et al.
Background: This study investigated survival in people living with HIV being followed-up from 5 and 10 years after antiretroviral therapy (ART) initiation in a multi-country Asian cohort. ...
Observational Study
Antiviral therapy. 2020;25(3):131-142. DOI:10.3851/IMP3358 2020
Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection [0.03%]
戴克拉斯维在感染基因四型丙型肝炎的埃及青少年中的药代动力学研究
Mogeb M Al-Nahari,Maggie M Abbassi,Fatma Se Ebeid et al.
Mogeb M Al-Nahari et al.
Background: Daclatasvir has potent antiviral activity against HCV infection when used in combination with sofosbuvir, however, its pharmacokinetics have not been described in adolescents. The aim is to determine the pharm...
HBV flare associated with immunosuppressive treatments: it is still dangerous in the third-generation antivirals era [0.03%]
免疫抑制治疗相关的乙肝病毒再激活仍然危险——即使在第三代抗病毒药物时代亦如此
Bilal Toka,Aydin Seref Koksal,Gülşen İskender et al.
Bilal Toka et al.
Background: There are limited data about the mortality and morbidity of patients with HBV flare related to immunosuppressive treatments (IST) in the third-generation antivirals era. Herein, we performed a multi-centric st...
The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report [0.03%]
静脉动脉体外膜肺氧合及鼻胃管喂养对阿巴卡韦、拉米夫定和多替拉韦药动学特征的影响：一例报告
Alison L Blackman,Emily L Heil,Aaron S Devanathan et al.
Alison L Blackman et al.
Background: Pharmacokinetic (PK) changes can affect antiretroviral (ARV) systemic exposure for critically ill patients living with HIV (CI-PLWH). Studies to guide ARV adjustments in this population are limited. ...
Case Reports
Antiviral therapy. 2020;25(2):115-119. DOI:10.3851/IMP3355 2020
CD4+:CD8+ T-cell ratio changes in people with HIV receiving antiretroviral treatment [0.03%]
接受抗逆转录病毒治疗的HIV感染者中的CD4+:CD8+t细胞比值变化
Maria J Vivancos-Gallego,Hajra Okhai,Maria J Perez-Elías et al.
Maria J Vivancos-Gallego et al.
Background: Cofactors associated with persistently abnormal CD4+:CD8+ T-cell ratio in people with HIV (PWH) on antiretroviral treatment (ART) might change over time as the population of people with HIV ages or as new ART ...
DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study [0.03%]
DAAs治疗HIV-HCV合并感染患者的疗效因素分析：一项真实世界研究
Loredana Alessio,Lorenzo Onorato,Vincenzo Sangiovanni et al.
Loredana Alessio et al.
Background: The aim of the present study was to evaluate in HIV-infected patients treated with a direct-acting antiviral agent (DAA)-based regimen the variables associated with sustained virological response (SVR) and the...
Multicenter Study
Antiviral therapy. 2020;25(4):193-201. DOI:10.3851/IMP3353 2020
Multidrug-resistant cytomegalovirus infection in a patient with granulomatosis with polyangiitis during immunosuppressive treatment [0.03%]
一名接受免疫抑制治疗的肉芽肿性多血管炎患者出现多重耐药巨细胞病毒感染
Giulia Piccirilli,Angela Chiereghin,Martina Maritati et al.
Giulia Piccirilli et al.
Cytomegalovirus (CMV) infection is a major complication in immunocompromised patients, including those with autoimmune diseases. Here, we describe the first case of granulomatosis with polyangiitis treated with steroids and cyclophosphamide...
Case Reports
Antiviral therapy. 2020;25(2):111-114. DOI:10.3851/IMP3352 2020
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort [0.03%]
基于PITER队列的艾尔巴韦/格拉瑞韦在成人及老年人中的实际应用：合并用药的前瞻性评价
Maria Giovanna Quaranta,Stefano Rosato,Luigina Ferrigno et al.
Maria Giovanna Quaranta et al.
Background: In patients treated for HCV infection, potential drug-drug interactions (DDIs) can occur among direct-acting antiviral drugs (DAAs) and comedications used. The real-life effectiveness and safety of elbasvir/gr...
Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice [0.03%]
比克恩丙胺联合恩曲他滨/替诺福韦阿拉芬酰胺的短期神经精神耐受性临床实践分析
Christian Hoffmann,Knud Schewe,Stefan Fenske et al.
Christian Hoffmann et al.
Background: Neuropsychiatric AEs (NPAEs) leading to dolutegravir (DTG) discontinuation were seen more frequently in real-world use than in randomized clinical trials (RCTs). The recently approved fixed-dose combination bi...
Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018 [0.03%]
瑞士HIV队列研究中注射毒品者和其他参与者长期幸存者的社会和心理健康差异：1980-2018年
Katharina Kusejko,Alex Marzel,Huyen Nguyen et al.
Katharina Kusejko et al.
Background: People living with HIV who were diagnosed before highly active antiretroviral therapy became available in 1996 and who survived at least 15 years after HIV diagnosis, termed long-term survivors (LTS), form a p...
Comparative Study
Antiviral therapy. 2020;25(1):43-54. DOI:10.3851/IMP3347 2020